RESUMEN
1. Challenges, strategies and new technologies in the field of biotransformation were presented and discussed at the fourth European Biotransformation Workshop which was held in collaboration with the joint ISSX/DMDG meeting on June 15, 2023 at the University of Hertfordshire in Hatfield, UK.2. In this meeting report we summarise the presentations and discussions from this workshop.3. The topics covered are listed below: Unusual biotransformation reactionsBiotransformation Workflows in Discovery utilising various softwares for structure elucidationBiotransformation software for the identification of peptide metabolitesAccelerator Mass Spectrometry (AMS) for endogenous and xenobiotic metabolite profilingMetabolite profiling using quantitative Nuclear magnetic resonance (NMR) and liquid chromatography coupled to inductively coupled plasma-mass spectrometry (LC-ICP-MS).
Asunto(s)
Biotransformación , Xenobióticos , Humanos , Cromatografía Liquida , Europa (Continente) , Espectrometría de Masas , Metabolómica , Xenobióticos/metabolismoRESUMEN
Challenges and opportunities in the field of biotransformation were presented and discussed at the 2nd European Biotransformation workshop which was conducted virtually in collaboration with the DMDG on November 24/25, 2021. Here we summarise the presentations and discussions from this workshop.The following topics were covered:Regulatory requirements and biotransformation studies for antibody drug conjugates (ADCs) and antisense oligonucleotides (ASOs).Solutions for mass spectral data processing of peptides and oligonucleotides.Future outsourcing needs in biotransformation for new modalities.Established quantitative and qualitative workflows for metabolite identification.New in vitro systems to study new chemical entities (NCEs) with low metabolic turnover.New strategies on the timing of the human ADME (absorption, distribution, metabolism, excretion) study and to investigate the impact of human microbiome on drug development.
Asunto(s)
Inmunoconjugados , Biotransformación , Humanos , PéptidosRESUMEN
1. Challenges and opportunities in the field of biotransformation were presented and discussed at the 1st European Biotransformation workshop which was conducted virtually in collaboration with the DMDG 27 January 2021. Here we summarize the presentations and discussions from this workshop.The following topics were covered:2. Needs for radiolabel for IND filing versus quantitation without standards.3. Applications of cyclic ion mobility in the field of biotransformation.4. Computational predictions of xenobiotic metabolism.5. Future (outsourcing) needs in biotransformation.6. Genotoxicity risk assessment of metabolites and qualification of impurities using metabolite data.7. Regulatory aspects of MIST.
Asunto(s)
Biotransformación , Inactivación MetabólicaRESUMEN
Non-cleavable linkers are used in a number of different modalities for various reasons, such as linking an active drug moiety to half-life extending molecules, to groups that enable a specific tissue or cell targeting or to facilitate active uptake into target cells. Non-cleavable linkers do not have a designated weak point in their structure that can lead to cleavage by proteases, hydrolases or chemically by pH changes. Consequently, when designing a conjugate, the choice of a non-cleavable over a cleavable linker is usually a consequence of pursuing a certain mode of action where the stability of the complex is more important than a fast liberation of the active moiety. Linkers of various length, polarity, stability and flexibility are used for different types of conjugates and the linker design is mostly driven by the particular purpose and desired mode of action. This article reviews non-cleavable linkers applied predominantly in Antibody Drug Conjugates (ADCs), and how they influence these conjugates in terms of ADME properties (absorption, distribution, metabolism and elimination) and safety.
Asunto(s)
Anticuerpos/efectos adversos , Anticuerpos/metabolismo , Descubrimiento de Drogas , Seguridad del Paciente , HumanosRESUMEN
Robust biocompatible solid-phase microextraction (SPME) devices were prepared using various alkyldiol-silica (ADS) restricted-access materials (RAM) as the SPME coating. The ADS-SPME approach was able to simultaneously fractionate the protein component from a biological sample, while directly extracting diazepam and the major metabolites N-desmethyldiazepam, oxazepam and temazepam, and overcame the present disadvantages of direct sampling in biological matrices by SPME. The devices were interfaced with an LC-MS system and an isocratic mobile phase was used to desorb, separate, and quantify the analytes. The calculated diazepam, nordiazepam, temazepam, and oxazepam detection limits were 20, 20, 30, and 35 ng/ml in heparinized blood, respectively. The method was confirmed to be linear over the range of 50-1000 ng/ml with an average linear coefficient (R2) value of 0.996. The injection repeatability and intra-assay precision of the method were evaluated over ten injections at concentrations of 50, 200, and 500 ng/ml, resulting in a R.S.D. of ca. 10%. The robustness of the ADS-SPME device was evaluated for future use in in vivo studies, providing many direct extractions and subsequent determination of benzodiazepines in blood. For the extraction of the peptides angiotensin I, II, and III from blood, a novel restricted access material with cation exchange properties was evaluated. The ion-exchange diol silica improved the extraction efficiency of peptides relative to the conventional ADS material with reversed phase extraction centers.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas/métodos , Preparaciones Farmacéuticas/sangre , Microscopía Electrónica de RastreoRESUMEN
Verapamil is a widely prescribed calcium antagonist, but suffers from extensive first pass metabolism. Despite its frequent use in drug metabolism a complete understanding of its metabolic pathway is still lacking. We thus investigated verapamil's metabolism in cultures of primary rat hepatocytes and isolated metabolites from cell culture media by solid phase extraction (SPE). In detail, we investigated their structure in multiple liquid chromatography-mass spectrometry (LC-MSn) experiments and found 25 phase I and 14 phase II metabolites. We showed many metabolites to be produced by oxidative dealkylation, and several yet unknown metabolites were identified that stem from hydroxylation and dealkylation reactions. Furthermore, we identified an array of glucuronides and, additionally, a glucoside. Finally, we investigated the enantioselective biotransformation of verapamil and found preferential metabolism of the S-enantiomers. In conclusion, this illustrates again the true complexity of verapamil's disposition.
Asunto(s)
Bloqueadores de los Canales de Calcio/metabolismo , Hepatocitos/metabolismo , Espectrometría de Masas/métodos , Verapamilo/metabolismo , Alquilación , Animales , Biotransformación , Bloqueadores de los Canales de Calcio/farmacocinética , Células Cultivadas , Masculino , Oxidación-Reducción , Ratas , Ratas Sprague-Dawley , Verapamilo/farmacocinéticaRESUMEN
1. Verapamil is a well-known and world-wide prescribed calcium antagonist, but it suffers from extensive first-pass metabolism. Although it has been marketed for many years, a complete understanding of its biotransformation in humans is still lacking. 2. The metabolism of verapamil was therefore investigated in cultures of primary human hepatocytes and in extracts of human urine after oral dosing. Identification of metabolites was done with LC-MS(n) and LC-NMR (600 MHz) to obtain in-depth information on its biotransformation products and definitive proof of the proposed chemical structures of metabolites. 3. Hyphenation of LC-MS(n) and LC-NMR was shown to be a powerful and effective platform for the identification of metabolites. Indeed, 21 Phase I and 16 Phase II metabolites were identified. Basically, all the Phase II metabolites (glucuronides) and 11 of the Phase I (oxidative) metabolites were not reported previously. 4. New insight into verapamil's biotransformation pathway is provided as well as evidence about its true complexity of metabolic disposal.
Asunto(s)
Bloqueadores de los Canales de Calcio/farmacocinética , Hepatocitos/metabolismo , Verapamilo/análogos & derivados , Verapamilo/farmacocinética , Biotransformación , Bloqueadores de los Canales de Calcio/orina , Células Cultivadas , Cromatografía Liquida , Remoción de Radical Alquila , Humanos , Hidroxilación , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Oxidación-Reducción , Verapamilo/metabolismo , Verapamilo/orinaRESUMEN
Verapamil is a common calcium antagonist described with antianginal, antihypertensive and antiarrythmic properties. The metabolites of verapamil have also shown pharmacological properties and therefore sample preparation and analysis techniques capable of metabolic screening for verapamil are important. In-tube SPME is a relatively new method integrating sample extraction, concentration and introduction into one single step without the use of organic solvents. The capability of in-tube SPME in bioanalysis has been reviewed but there has been no application described in the field of drug metabolism. Since automation and interfacing of in-tube SPME coupled to liquid chromatography-mass spectrometry (LC-MS) is possible, we confirm in this study that it is a powerful method to monitor the main metabolites of verapamil in various biological matrices like plasma, urine and cell culture media. Further, we show that it could also be used in routine pharmacokinetics measurements. An in-tube SPME LC-MS method was developed to extract and analyze the metabolic profile of verapamil from biological matrices. The detection limit for verapamil, gallopamil, norverapamil and PR22 were 52, 53, 65 and 83 ng/ml (UV detection) and 5, 6, 6 and 8 ng/ml (MS detection), respectively. The precision of the method was calculated in various biological matrices and the average % R.S.D. (N=5) for verapamil, gallopamil, norverapamil and PR22 was 3.9, 3.7, 3.8 and 4.3% (MS detection), respectively. The linear dynamic range was determined to be 100-800 ng/ml (UV detection) with a total sample preparation and analysis time of 34 min.
Asunto(s)
Verapamilo/análisis , Verapamilo/metabolismo , Animales , Cromatografía Líquida de Alta Presión/métodos , Cromatografía Líquida de Alta Presión/estadística & datos numéricos , Humanos , Masculino , Espectrometría de Masas/métodos , Espectrometría de Masas/estadística & datos numéricos , Ratas , Ratas Sprague-Dawley , Verapamilo/químicaRESUMEN
A substantial number of drugs act either directly or indirectly on the heart, but surprisingly, little is known about drug oxidation in the heart. We therefore investigated the metabolism of the calcium antagonist verapamil in microsomal fractions isolated from the left and right ventricle of heart muscle and in primary cultures of cardiomyocytes of adult rats. Metabolism of verapamil proceeded predominantly with microsomal fractions isolated from the right ventricle of rat heart, and in liquid chromatographic-tandem mass spectrometry (LC-MS/MS) and LC-MS(3) experiments four metabolites (M1-M4) could be identified. Furthermore, the intermediate biotransformation products M5 to M8 could additionally be identified in cultures of primary cardiomyocytes, thus providing new insight into the mechanisms of the N-dealkylation and O-demethylation pathway of verapamil. We show metabolism of verapamil to be predominant in the right ventricle of the heart, and the data reported herein may explain metabolic inactivation and/or adverse drug reactions of certain cardiovascular drugs on the basis of tissue specific metabolism.
Asunto(s)
Bloqueadores de los Canales de Calcio/metabolismo , Miocardio/metabolismo , Verapamilo/metabolismo , Animales , Bloqueadores de los Canales de Calcio/farmacocinética , Células Cultivadas , Masculino , Espectrometría de Masas , Microsomas/metabolismo , Miocardio/citología , Ratas , Ratas Sprague-Dawley , Verapamilo/farmacocinéticaRESUMEN
A method for inhalative exposure of minipigs to aerosols and gases has been developed. Minipigs are exposed via mask inhalation to the test substance using a computer-controlled exposure system that permits simultaneous exposure of groups of four animals in parallel to different controlled dose levels. We studied inhalation treatment of verapamil, a cardiovascular drug, and show good absorption and favorable pharmacokinetics when compared with iv drug application. The results shown in this study encourage inhalation studies with the Göttingen minipig.